Last reviewed · How we verify

HAL Allergy — Portfolio Competitive Intelligence Brief

HAL Allergy pipeline: 2 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PURETHAL Birch, 20.000 AUM/ml PURETHAL Birch, 20.000 AUM/ml marketed Allergen immunotherapy extract Birch pollen allergens (Bet v 1 and related proteins) Immunology / Allergy
PURETHAL Grasses, 20.000 AUM/ml PURETHAL Grasses, 20.000 AUM/ml marketed Allergen immunotherapy extract Grass pollen allergens (IgE and T-cell epitopes) Immunology / Allergy
SUBLIVAC® Grasses treatment SUBLIVAC® Grasses treatment phase 3 Allergen immunotherapy Immunology
SUBLIVAC® Grasses/Placebo treatment SUBLIVAC® Grasses/Placebo treatment phase 3 Allergen immunotherapy Immunology
PURETHAL Mites 50,000 AUeq/ml PURETHAL Mites 50,000 AUeq/ml phase 3 Allergen immunotherapy (sublingual) Dust mite allergens (Der p and Der f proteins) Immunology / Allergy
SUBLIVAC FIX Birch SUBLIVAC FIX Birch phase 3 Sublingual immunotherapy (SLIT) Birch pollen allergens (Bet v 1 and related epitopes) Immunology / Allergy

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ALK-Abelló A/S · 2 shared drug classes
  2. Laboratorios Leti, S.L. · 2 shared drug classes
  3. Medical University of Silesia · 2 shared drug classes
  4. Anergis · 1 shared drug class
  5. Beijing Tongren Hospital · 1 shared drug class
  6. Clinique Spécialisée en Allergies de la Capitale · 1 shared drug class
  7. Johns Hopkins University · 1 shared drug class
  8. The University of Texas Medical Branch, Galveston · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for HAL Allergy:

Cite this brief

Drug Landscape (2026). HAL Allergy — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hal-allergy. Accessed 2026-05-13.

Related